On February 11, 2020, the Federal Trade Commission (FTC) announced that it sued two companies to stop them from continuing to make false claims about their bone and joint health products, Ostinol (ZyCal Bioceuticals) and StimTein (Excellent Marketing Results, Inc. (EMR)). EMR has agreed to settle the FTC charges and will pay $145,000, which may be used to refund customers. The FTC is proceeding with litigation against ZyCal and its president, James Scaffidi.
According to the FTC, the pills sold by both EMR and Zycal use the same active ingredient, Cyplexinol, and both companies claimed that their pills grow bone and cartilage, which relieve joint pain. Both companies also used deceptive testimonials to sell their products.
EMR's settlement bans the company and its president, Michael McGahee, "from misrepresenting the results of any scientific study or endorsement and requires them to disclose any material connections they have with endorsers." It also imposes a $3.6 million judgment against EMR and McGahee, which will be partially suspended after they pay $145,000.
For other Recalls and Warnings click HERE.For information about reporting serious reactions and problems with medical products to the U.S. Food and Drug Administration through its MedWatch reporting program, please go to http://www.fda.gov/medwatch/how.htm.
Sign up for FREE Newsletter
BECOME A MEMBER
Instant Access to Reviews for OVER 1,000 Products!